Has Devanshu Verma, MD received payments from drug or device companies?

Yes. Drug and device makers reported $614 in general payments to Devanshu Verma, MD across 15 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Devanshu Verma, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Devanshu Verma, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Devanshu Verma, MD

Rheumatology · Newark, DENPI 1619350451

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $514 of the $614 with a category attached, or 83.7%. 7 manufacturers reported payments, led by Janssen Scientific Affairs, LLC at 25.8% of the total.

$614in general payments, 2019–2025

Across 15 payments — averaging $40.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Janssen Scientific Affairs, LLC$158
GSK$108
AbbVie$102
Johnson & Johnson$100
Amgen$67
AstraZeneca$40
plus $39 from 1 others

What the payments were for

Food & beverage$51484%
Education$10016%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Janssen Scientific Affairs, LLC	2	$158
GSK	1	$108
AbbVie	5	$102
Johnson & Johnson	1	$100
Amgen	3	$67
AstraZeneca(2 entities)	2	$40
Bayer	1	$39

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few rheumatology providers in Delawareto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024

$45,260

Medicare patients

214

Services billed

377

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Humira(Cf) PenAdalimumab	44	$312,942
Actemra ActpenTocilizumab	41	$169,110
KevzaraSarilumab	26	$108,193
Enbrel SureclickEtanercept	15	$105,455
BenlystaBelimumab	17	$77,158
Evenity (2 Syringes)Romosozumab-Aqqg	19	$46,773
Hydroxychloroquine Sulfate	222	$10,756
Mycophenolate Mofetil	38	$6,888
MethotrexateMethotrexate Sodium	130	$4,093
Colchicine	40	$1,854
Prednisone	204	$1,354
Celecoxib	14	$1,309
Leflunomide	21	$979
Azathioprine	16	$895
Duloxetine Hcl	46	$776

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
GSKBenlysta	$108	$77,15817 claims
AmgenEvenity (2 Syringes)	$67	$46,77319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few rheumatology providers in Delawareon file to place this against a meaningful peer group, so we don't.

Other rheumatology in Newark

Amy ZhangNewark$8K
Pietro RoccaNewark$2K
Douglas LieneschNewark$469
Sheerin JavedNewark$42
Jose PandoLewes$93K
Lourdes AponteLewes$20K
Jinsong ZhangDover$11K
Philip SchwartzWilmington$10K
Ivonne HerreraSeaford$9K
Surjeet DheerDover$7K

See the full list for Delaware →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →